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The Mre11/Rad50/Nbs1 protein complex plays cen-
tral enzymatic and signaling roles in the DNA-
damage response. Nuclease (Mre11) and scaffolding
(Rad50) components of MRN have been extensively
characterized, but the molecular basis of Nbs1 func-
tion has remained elusive. Here, we present a 2.3A˚
crystal structure of the N-terminal region of fission
yeast Nbs1, revealing an unusual but conserved
architecture in which the FHA- and BRCT-repeat
domains structurally coalesce. We demonstrate
that diphosphorylated pSer-Asp-pThr-Asp motifs,
recently identified as multicopy docking sites within
Mdc1, are evolutionarily conserved Nbs1 binding
targets. Furthermore, we show that similar phospho-
motifs within Ctp1, the fission yeast ortholog of
human CtIP, promote interactions with the Nbs1
FHA domain that are necessary for Ctp1-dependent
resistance to DNA damage. Finally, we establish
that human Nbs1 interactions with Mdc1 occur
through both its FHA- and BRCT-repeat domains,
suggesting how their structural and functional inter-
dependence underpins Nbs1 adaptor functions in
the DNA-damage response.
INTRODUCTION
Genomic integrity is constantly challenged by the generation of
DNA lesions, of which double-stranded breaks (DSBs) are
generally considered the most toxic. DSBs can arise through
the actions of DNA-damaging chemicals and ionizing radiation,
but also occur at sites of stalled DNA replication and as interme-
diates during programmed genomic rearrangements such as
VDJ recombination, immunoglobulin class switching, and mei-
otic recombination. DNA-damage detection initiates a com-
plex and orchestrated set of intracellular responses involving100 Cell 139, 100–111, October 2, 2009 ª2009 Elsevier Inc.kinase-signaling cascades, cell-cycle checkpoint activation,
and the deployment of DNA-repair proteins (Riches et al.,
2008). Central to these processes is a diverse group of adaptor
and scaffold proteins that function as platforms for the assembly
of multiprotein complexes through the combinatorial activities
of phosphoserine/threonine binding protein modules. These
include forkhead-associated (FHA), Brca1 C-terminal (BRCT)-
repeat, Polo-box,WW,andWD40-repeatdomains,which interact
with specific motifs after their phosphorylation by DNA damage-
activated or cell cycle-responsive serine/threonine kinases.
Human Nbs1 (also known as Nibrin or p95) is a 754 amino acid
residue subunit of the Mre11-Rad50-Nbs1 (MRN) complex,
which binds to DSBs and acts as a bridge to hold the DNA
ends in close proximity and promote their rejoining (Williams
et al., 2007). Nbs1 was originally identified as the gene mutated
in Nijmegen breakage syndrome (NBS), a rare autosomal-reces-
sive human disease characterized by immune disorders, micro-
cephaly, growth retardation, hypersensitivity to ionizing radia-
tion, and predisposition to lymphoid cancers (Carney et al.,
1998; Matsuura et al., 1998; Varon et al., 1998). Although homo-
zygous null Nbs1 mutations are embryonic lethal in mouse
models (Zhu et al., 2001), these human diseases are character-
ized by a variety of hypomorphic mutations that can occur
throughout the NBS1 gene.
Many NBS phenotypes overlap with those of another cancer-
predisposition syndrome, ataxia telangiectasia, which is caused
by defects in the protein kinase ATM (ataxia telangiectasia
mutated). It is now evident that Nbs1 functions in ATM activation,
while also serving as a substrate for ATM-mediated phosphory-
lation on Ser-278 and Ser-343 (Difilippantonio andNussenzweig,
2007). Nbs1 makes direct interactions with ATM and Mre11
through distinct motifs within its C-terminal region (Desai-Mehta
et al., 2001; Falck et al., 2005; You et al., 2005), whereas the
Nbs1 N-terminal region contains FHA and BRCT motifs that
are characteristic ofmany other DNA-damage response proteins
and which often mediate phospho-dependent protein-protein
interactions. Functionally, Nbs1 seems to play key roles in
most or all of the DNA-damage-checkpoint signaling functions
of the MRN complex (D’Amours and Jackson, 2002) through
interactions with a number of proteins, the best characterized
being Mdc1 (mediator of the DNA-damage checkpoint 1) and
ATM itself (Chapman and Jackson, 2008; Falck et al., 2005;
Lukas et al., 2004; Melander et al., 2008; Spycher et al., 2008;
Wu et al., 2008; You et al., 2005; Zhao et al., 2000). However,
Nbs1 activities do not appear to be restricted to checkpoint
signaling. Indeed, more direct contributions of Nbs1 to DSB
repair are suggested by the observation that DNA-damage
sequestration of CtIP, a molecule required for efficient DSB
resection (Limbo et al., 2007; Sartori et al., 2007), is facilitated
through direct interactions with Nbs1 in human cells (Chen
et al., 2008).
In spite of the array of Nbs1 activities, little is currently known
about how it mediates its diverse protein interactions at the
molecular level. Here, we describe an integrated structural,
biochemical, genetic and cell-biological analysis of the Nbs1
N-terminal FHA/BRCT-repeat region. This work reveals how
the conserved architecture and phospho-dependent protein
binding functions of the Nbs1 N terminus play crucial roles in
mediating Nbs1 adaptor functions in the DNA-damage response
to promote DSB signaling and repair.
RESULTS
Structure of the Nbs1 N-Terminal Region Reveals
an Unusual FHA/BRCT-Repeat Architecture
After extensive screening of Nbs1 proteins from several species,
we were able to express and purify 382 and 323 residue
N-terminal fragments of human Nbs1 (hNbs1) and yeast Schizo-
saccharomyces pombe Nbs1 (spNbs1), respectively. While the
human protein has not, as yet, yielded crystals, we were able
to solve the structure of the S. pombe protein by single-wave-
length anomalous diffraction methods at an initial resolution of
2.6A˚, and then further refined it against data extending to 2.3A˚
spacing collected from crystals of reductively methylated protein
(Table 1). Representative electron density for the SAD-phased
selenomethionine structure and the final refined methylated
protein are shown in Figure S1 (available online).
Overall, the spNbs1 N terminus is extended, with approximate
dimensions of 95 3 30 3 25 A˚ (Figure 1A). The N-terminal 114
residues adopt a b sandwich fold characteristic of FHA domains:
small phospho-dependent binding modules that function
through recognition of phosphothreonine (pThr)-containing
motifs in target proteins (Mahajan et al., 2008). Notably, the
spNbs1 structure reveals the presence of tandem BRCT
repeats, despite the lack of any significant homology between
the second motif and other known BRCT domains. In the light
of previous sequence analyses of various Nbs1 orthologs
(Becker et al., 2006) and comparison of our spNbs1 structure
with the NMR analysis of the second BRCT repeat from Xenopus
laevis Nbs1 (Xu et al., 2008) (Figure 1B), it seems that the FHA/
BRCT2 composition is indeed conserved in all eukaryotic Nbs1
proteins. Most significantly, our structure reveals a structural
fusion of the FHA domain and first BRCT repeat. Rather
than forming a ‘‘beads-on-a-string’’ arrangement as might be
expected in a classical modular domain system, they are asso-
ciated through a substantial interface within which 2150 A˚2 of
solvent-accessible surface is buried (Figure 1C). The bulk ofthe interfacial interactions occur between the base of the FHA
domain and a1, a3, aL1, and a1/b2 loop of BRCT1. Additional
stabilizing contacts are provided by the helical insertion in the
FHA domain (a0) and the a1-b2/b2-b3 loops from BRCT1. Over-
all, the relative orientations of the FHA, BRCT1, and BRCT2
domains for three independent molecules (two methylated, one
unmethylated) in the two crystal forms are rather similar with the
largest deviations being associated with the BRCT2 regions
(Figure 1D, top). This, together with the significantly elevated
crystallographic B factors associated with BRCT2 (Figure 1D,
bottom), suggests that the FHA-BRCT1 domains form a com-
pact structural unit that is more flexibly linked to the second
BRCT-repeat motif.
The Nbs1 ‘‘Supermodular’’ Architecture Is Conserved
Several lines of evidence indicate that the overall architecture
observed for spNbs1 is common to all eukaryotic Nbs1 ortho-
logs. Thus, although limited sequence identity for interfacial
Table 1. Crystallographic Statistics
SpNbs1 (SeMet) SpNbs1 (Meth)
Space group P21212 P21
Unit cell (A˚) a = 55.5, b = 62.4,
c = 93.4
a = 55.2, b = 64.9,
c = 106.4, b = 96.1
Number of molecules/au 1 2
Wavelength (A˚) 0.9698 0.9757
Resolution (A˚) 20.0–2.60 (2.72–2.60) 20.0–2.3 (2.40–2.30)
Completeness (%) 100.0 (100.0) 94.5 (66.5)
Total observations 270,325 113,597
Unique observations 19,822 30,800
Redundancy 13.6 (6.6) 3.7 (3.0)
Rmerge (%)
a 9.7 (44.8) 7.0 (40.4)
<I/s (I) > 25.6 (4.5) 14.9 (2.7)
Structure Solution
Phasing method SAD Molecular
replacement
Selenium sites/molecule 8
Refinement
Resolution (A˚) 15–2.6 15.0–2.3
R (%)b 22.4 21.5
Rfree (%) 26.8 26.3
rmsd bond lengths (A˚2) 0.008 0.008
rmsd bond angles () 1.2 1.1
Ramachandran plot
Preferred regions (%) 94.0 96.0
Allowed regions (%) 4.5 3.3
Outliers (%) 1.5 0.7
PDB accession 3I0M 3I0N
aRmerge = ShSijIh,i  < Ih > j/ ShSiIh,i, where Ih,i is the intensity of the indi-
vidual reflections and < Ih > is the mean intensity over symmetrically
equivalent reflections.
bR = ShkFo,hj  jFc,hk/ShjFo,hj, where jFo,hj and jFc,hj are observed and
calculated structure factor amplitudes, respectively; Rfree was calculated
with 5% of the data.Cell 139, 100–111, October 2, 2009 ª2009 Elsevier Inc. 101
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Figure 1. Structure of the S. pombe FHA/BRCT Region
(A) Ribbons representation of the spNbs1 FHA/BRCT region with b strands shown as arrows and a helices as tubes. The FHA, BRCT1, linker, and BRCT2 domains
are colored red, green, magenta, and blue, respectively, with the major secondary structural elements labeled. All structural representations were generated with
PyMOL (http://pymol.sourceforge.net/).
(B) Structural superposition (top) shows a remarkable similarity between the second BRCTmotif of spNbs1 and that of Xenopus laevis (PDBID: 2K2W) with a root
mean square deviation of 2.0 A˚ for 65 matched Ca atoms from each domain. The ‘‘L3’’ loop that contains a major site of ATM-phosphorylation corresponding to
Ser-278 in hNbs1 (Zhao et al., 2000) is replaced by a partially disordered helical loop in spNbs1. The resulting structure-based sequence comparison (bottom)
shows only a general conservation of non-polar residues that form the hydrophobic BRCT core.
(C) FHA- and BRCT1-domain interactions are shown in an ‘‘open book’’ representation. The contact areas of the FHA with BRCT1 (green) and BRCT1 with the
FHA (red) represent >2000A˚2 of total buried solvent-accessible surface.
(D) Top, least-squares superposition of the three crystallographically independent molecules from two crystal forms using the 114 Ca atoms from each FHA
domain shows that the relative arrangements of FHA and BRCT1 are nearly identical although some small displacements of BRCT2 are evident. Bottom, plot
of crystallographic B factors for Ca atoms in the selenomethionine spNbs1 structure. The positions of the FHA domain, BRCT repeatsn and linker region are
indicated by the horizontal bar with the same coloring as in (A). A similar distribution is seen in methylated spNbs1 structure (data not shown).residues is evident between spNbs1 and hNbs1, the nonpolar
character of amino acid residues that contribute core FHA-
BRCT1 interactions is conserved (Figure 2A). In addition, a strip
of conserved hydrophobic surface follows the path of the linker
extending from the BRCT1-FHA interface to BRCT2. Notably,
the N-terminal Met-Trp pair of spNbs1 is buried in the structure
and forms an intrinsic part of the non-polar FHA-BRCT1 interface
(Figure 2B). Trp-2 is highly conserved in animals and fungi, and,
because of its bulk, it presumably insulates the initiator methio-
nine from cotranslational excision (Giglione et al., 2004). Plants,
however appear to have followed a different evolutionary path to
the same structural end point whereby an extra valine residue is
positioned to take the place ofMet-1 andmaintain the integrity of
the FHA-BRCT1 interface after more efficient methionine amino-
peptidase cleavage expected when small hydrophobic residues
are present in the second position (Martinez et al., 2008). Overall,
the importance of the structure around Met-1/Trp-2 is exempli-
fied by the insolubility/aggregation of recombinant Nbs1
expressed with either N-terminal GST or hexahistidine affinity102 Cell 139, 100–111, October 2, 2009 ª2009 Elsevier Inc.tags (data not shown). These observations, together with
the absence of any significant ‘‘linker’’ region between the
C terminus of the FHA domain and N terminus of BRCT1 in all
Nbs1 sequences (Becker et al., 2006) (Figure 2C), support our
contention that the structural coupling and precise spatial appo-
sition of the FHA and BRCT domains is likely to be crucial for
Nbs1 functions in all eukaryotes.
Structural Context of Human Disease-Associated Nbs1
Mutations
The apparent structural conservation between Nbs1 orthologs
allows us to place in a molecular context various human
disease-associated Nbs1 mutations that are located within the
FHA/BRCT region. To date, around 90% of patients suffering
from NBS are homozygous or heterozygous for a founder muta-
tion,657del5, a 5bpdeletion in exon 6within thecoding region for
the BRCT1-BRCT2 linker that results in production of C- and
N-terminally truncated proteins termed p26 and p70, respec-
tively (Maser et al., 2001) (Figure S2A). In addition, a number of
germline and somaticmissensemutations in theNbs1N-terminal
region have been noted in patients suffering from NBS and in
a variety of cancers (http://www.nijmegenbreakagesyndrome.
net/) (Figure S2B). Although the degree to which thesemutations
might contribute to disease is mostly unclear, we note that four
(T148I, L150F, I171V, and V210F) lie within a significant hydro-
phobic cluster in the BRCT1-domain core and the BRCT1-linker
interface, suggesting that these lesions may result in structural
perturbations, potentially contributing to Nbs1 protein instability
in affected individuals (Figure S2C). Nonetheless, it remains
possible that somemutations (such as V26I located immediately
C-terminal to the highly conserved FHA phosphopeptide binding
residue Arg-27) directly affect phospho-dependent and/or phos-
pho-independent interaction surfaces on Nbs1.
Evolutionarily Conserved Binding of pSDpTD-like Motifs
to the Nbs1 FHA Domain
The functional importance of the Nbs1 FHA/BRCT region is well
established, but the molecular basis for this remains obscure.
Recruitment of theMRN complex to subnuclear foci at DSB sites
has been proposed to involve a direct interaction between
hNbs1 and gH2AX (Kobayashi et al., 2002), the ATM-phosphor-
ylated form of variant histone H2A that serves as a major marker
for damaged chromatin. However, by isothermal titration calo-
rimetry (ITC), we were unable to detect any interactions of
recombinant hNbs1 or spNbs1 proteins with peptides represent-
ing human orS. pombe gH2AX (Figure S3). This confirms the lack
of binding of hNbs1 to gH2AX peptides observed previously by
peptide pulldown assays (Chapman and Jackson, 2008) and
Figure 2. A Conserved FHA/BRCT1 Archi-
tecture
(A) Conserved hydrophobic residues (orange)
within S. pombe and human Nbs1 proteins (top)
mapped onto the spNbs1 crystal structure (bot-
tom) show that major, surface exposed nonpolar
patches (orange) common to both distantly related
orthologs are located primarily at the FHA/BRCT1
and BRCT1-linker interfaces.
(B) Surface representation showing how the highly
conserved N-terminal methionine/tryptophan
motif is buried at the interface between the FHA
domain (red surface) and BRCT1 (green surface).
(C) The FHA and BRCT1 domains (pink and green,
respectively) are connected through a short linker
(orange) in all orthologs (Sp, S. pombe; Sj, S. japo-
nicum; Sc, S. cerevisiae; Hs, Homo sapiens; Xl,
Xenopus laevis).
strongly suggests that direct gH2AX-
binding by Nbs1 is unlikely to contribute
significantly to MRN localization to
damaged chromatin.
More recently, the mammalian MRN
has been shown to be indirectly seques-
tered to DNA-damage sites through
Nbs1 interactions with a cluster of six
diphosphorylated casein-kinase 2 (CK2)
target sites within Mdc1, each with a
core consensus sequence phospho-Ser, Asp, phospho-Thr,
Asp (pSDpTD) (Chapman and Jackson, 2008; Melander et al.,
2008; Spycher et al., 2008; Wu et al., 2008). This Mdc1/MRN/
ATM complex is in turn tethered to damaged chromatin via inter-
actions between the Mdc1 BRCT-repeat domain and gH2AX
(Lee et al., 2005; Stucki et al., 2005). Consistent with the depen-
dence of Mdc1-Nbs1 interactions on the Nbs1 FHA domain
(Chapman and Jackson, 2008; Lukas et al., 2004; Melander
et al., 2008; Spycher et al., 2008; Wu et al., 2008), we found
that the hNbs1 fragment bound a synthetic Mdc1 pSDpTD motif
peptide (Mdc1 residues 325–336) with an affinity of 1 mM
(Figure 3A, upper panel; Table S1) and a stoichiometry signifi-
cantly greater than 1:1 (see below). In addition, and in spite of
the absence of any clear Mdc1 orthologs in yeast, the purified
spNbs1 protein bound the same Mdc1 phosphopeptide with
a slightly higher affinity of 0.5 mM (Figure 3A, lower panel). By
contrast, neither spNbs1 nor hNbs1 bound to a peptide of the
same sequence in which the threonine was not phosphorylated,
reflecting the acute pThr-selectivity of FHA domains.
Although the spNbs1 FHA domain is closely related to previ-
ously determined FHA-domain structures, superposition with
a canonical Chk2 FHA-phosphopeptide complex (Li et al.,
2002) predicts severe steric clashes of the spNbs1 FHA domain
with the phosphopeptide. This results from phenylalanine/tyro-
sine substitutions in Nbs1 at a conserved position (Phe-77 in
spNbs1) normally occupied by an asparagine in other FHA
domains (Asn-166 in Chk2) (Figures S4A and 3B). These obser-
vations suggest that bound phosphopeptide ligands follow
a different path across the spNbs1 FHA binding surface,Cell 139, 100–111, October 2, 2009 ª2009 Elsevier Inc. 103
Figure 3. Yeast and Human Nbs1 Bind to Mdc1 pSDpTD-Motif Peptides
(A) ITC experiments demonstrate that purified proteins of both hNbs1 (top) and spNbs1 (bottom) bind diphosphorylated synthetic Mdc1 pSDpTD-motif peptides
(closed circles). No binding of hNbs1 and spNbs1 to identical sequences containing a singly phosphorylated serine residue was detectable (open triangles).
(B) The phosphopeptide binding region of the FHA domain of spNbs1 is shown as a surface representation with conserved residues forming a potential binding
channel highlighted. A superimposed phosphopeptide (yellow sticks) from the Chk2-FHA complex structure (Li et al., 2002) (PDB ID: 1GXC) highlights significant
steric clashes with Phe-77 of spNbs1 and the phosphopeptide backbone.
(C) Binding contributions of residues that form the predicted ligand-binding surface of spNbs1 were assessed by mutagenesis and ITC and compared with wild-
type spNbs1 binding to the Mdc1 pSDpTD di-phosphopeptide (black line).
(D) Nbs1 FHA-dependent phospho-interactions promote normal growth and resistance to DNA damage. Five-fold serial dilutions of the indicated strains were
plated on control medium (YEA) or medium supplemented with the indicated drugs and then incubated for 3 or 5 days (HU) at 30C (UV, ultraviolet light; phleo,
phleomycin; CPT, camptothecin; MMS, methyl methanesulphonate; HU, hydroxyurea). The additional sensitivity of the nbs1G103D mutant compared with nbs1
s10 may result from differences in genetic background.interacting with a surface groove formed by K76-F77 and S42-I-S-
K45 (Figure 3B). Thesemotifs form the b6-b7/b7-b8 loops that are
more distant from one another in Nbs1 than in other FHA struc-
tures and are instead connected through a bridging water mole-
cule. This generates a somewhat polar floor for the peptide-
binding site and potentially provides for some structural flexibility
in the relative juxtaposition of the peptide-binding loops. Lys-76
and Lys-45 each lie close to the pThr-binding site and potentially
contact the phosphoryl moiety directly (Figure S4B), while Gly-
103 and Ser-42 structure the rear of the pocket.
The above ideas were tested by site-directed mutagenesis.
Significantly, of the three conserved basic residues located
around the canonical FHA-domain binding site, the largest effect
on binding to the Mdc1 pSDpTD peptide was observed for
alanine substitution of the highly conserved Arg-27 residue (cor-
responding to Chk2 Arg-117; Figure S4) which reduced apparent
binding affinity 100-fold (Figure 3C; Table S1). More modest104 Cell 139, 100–111, October 2, 2009 ª2009 Elsevier Inc.effects were seen for the K76A and K45A mutations, which
reduced apparent affinity 7- and 5-fold, respectively. A G103D
mutation has been implicated in the slow growth and DNA-
damage hypersensitivity of the S. pombe nbs-s10 strain identi-
fied in a mutagenesis screen (Akamatsu et al., 2008). Given its
structural context, we speculated that this substitution might
directly affect phosphopeptide binding, and, as shown in
Figure 3C, this is clearly the case.
To explore the functional relevance of the somewhat unusual
FHA-mediated binding mode implied by the above data, we
introduced the same mutations into S. pombe cells and deter-
mined their effects on cell growth and sensitivity to various
DNA-damaging agents. Consistent with previous findings (Aka-
matsu et al., 2008), a strain bearing the spNbs1 G103D mutation
exhibited slow growth and hypersensitivity to a range of agents
that cause DNA damage and/or perturb DNA replication
(Figure 3D). Moreover, a strain bearing the R27A mutation that
Figure 4. Conserved pSDpTD-like Motifs in Ctp1 Contribute to DNA Repair in S. pombe
(A) Conservation of pSDpTD-related motifs between human Mdc1 and the yeast proteins Lif1 and Ctp1 (Hs, Homo sapiens; Sc, Saccharomyces cerevisiae; Sp,
Schizosaccharomyces pombe). The core SDTD motif is highlighted. The asterisk denotes the C terminus of the full-length Lif1 protein.
(B) Ctp1 overexpression suppresses the DNA damage sensitivity of the Nbs1 FHA phosphopeptide binding mutants. Indicated strains were transformed with
a multicopy plasmid, pSP102 expressing either Nbs1 or Ctp1, or with an empty control plasmid. Five-fold serial dilutions of the indicated strains were plated
on control medium (YPA-leu) or medium supplemented with the indicated drugs and then incubated for 3 days at 30C.
(C) Ctp1 SDTD-like sites are phosphorylated in vivo. eGFP-tagged wild-type or mutant Ctp1 was immunoprecipitated from extracts prepared from cultures of the
indicated S. pombe strains, grown in the presence or absence of phleomycin (10 mg, 3 hr). Immunoprecipiates were either treated or mock treated with l-phos-
phatase (NEB) before immunoblotting with the indicated antisera. The horizontal bars in the upper panel show the combination of alanine-substitutions in the 2TA
and 3TA Ctp1 mutants.
(D) DNA damage-induced hyperphosphorylation of Ctp1 is dependent on the integrity of Nbs1 and priming by CK2-like phosphorylation. Exponentially growing
cultures of the indicated strains were treated as in (C) and harvested, and extracts were immunoblotted with the indicated antibodies. Arrow indicates hyper-
phosphoryated form of Ctp1.severely reduced phosphopeptide binding in vitro closely
mimicked the slow-growth and DNA-damage hypersensitivity
phenotypes of the nbs-s10 strain, implying that the G103D/
s-10 phenotypes are not merely caused by improper Nbs1
folding. By contrast, strains with alanine substitutions of Lys-
45 or Lys-76, which resulted in more modest phosphopeptide
binding defects, were not slow growing and exhibited DNA-
damage sensitivity profiles close to those of the wild-type strain
(Figure 3D). Nevertheless, these two strains showed significant
hypersensitivity when exposed to increased concentrations of
methyl methane sulphonate, presumably reflecting the modest
impairment of phospho-binding activity observed in ITC experi-
ments. Collectively, these structural, biochemical, and functional
analyses thus provided strong evidence that FHA-dependentphosphopeptide interactions by spNbs1 are required for its roles
in promoting normal growth and resistance to DNA-damaging
agents.
Mdc1-like Sites in S. pombe Ctp1 Are Phosphorylated
In Vivo
The above findings suggested that binding to pSDpTD-like
motifs is an important, evolutionarily conserved function for
Nbs1. In this regard, we noted that phospho-dependent interac-
tions of budding yeast Nbs1/Xrs2 with the XRCC4 homolog, Lif1
(Matsuzaki et al., 2008), have previously been shown to require
the Xrs2 FHA domain and two putative phosphorylation sites
(Thr-387 and Thr-417) within Lif1 (Palmbos et al., 2008), both of
which are clearly related to the Mdc1 SDTD motifs (Figure 4A).Cell 139, 100–111, October 2, 2009 ª2009 Elsevier Inc. 105
While S. pombe has no clear Mdc1 or Lif1 orthologs, we were
intrigued by previous observations that the growth and DNA-
repair defects of the nbs-s10 strain (harboring the functionally
disruptive G103D FHA-domain mutation) are rescued by Ctp1
overexpression (Akamatsu et al., 2008). We confirmed this and
further showed that Ctp1 overexpression can suppress the
impaired growth and DNA-damage hypersensitivity of a strain
carrying the spNbs1 R27A FHA mutation that reduces phos-
pho-binding function by 100-fold in vitro (Figure 4B).
These data suggested to us that the spNbs1 FHA domain
might promote interactions with Ctp1, and that spNbs1 FHA-
domain defects can thus be circumvented by Ctp1 overexpres-
sion. In line with this idea, like its human counterpart CtIP (Chen
et al., 2008; Sartori et al., 2007), S. pombe Ctp1 is a phospho-
protein that is recruited to DSBs in a MRN-dependent fashion
to promote DSB resection and DNA repair by homologous
recombination (Akamatsu et al., 2008; Limbo et al., 2007). More-
over, while inspecting the Ctp1 sequence, we observed that it
contains two motifs (site 1 and site 2) closely resembling the
CK2-consensus, Nbs1-binding sites of Mdc1 and Lif1 (Fig-
ure 4A).
To investigatewhetherCtp1 is phosphorylatedon the site 1 and
2 motifs in vivo, we generated a phospho-specific antibody
directed against a diphosphorylated peptide comprising Ctp1
Ser-87 and Thr-89 (pS87pT89). We then used this antibody to
probeCtp1 immunoprecipitates fromextractsofS.pombe strains
expressing epitope-tagged wild-type Ctp1 or Ctp1 mutants
(‘‘2TA’’ and ‘‘3TA’’) in which the Thr residues in site 1 or site 2
were converted to nonphosphorylatable Ala residues (Fig-
ure 4C). Importantly, while the Ctp1 pS87pT89 antibody recog-
nized wild-type Ctp1, its immunoreactivity was lost in the case
of the mutant proteins, thus revealing that Ctp1 Site 2 (Ser-87/
Thr-89) is phosphorylated in vivo. Consistent with this, we noted
that the wild-type Nbs1 derivative migrated more slowly on
SDS-polyacrylamide gels than themutant proteins, while l phos-
phatase treatment converted all proteins to a faster migrating
form. Collectively, these findings indicated that Ctp1 is subject
to multiple phosphorylations in vivo, some of which reside in the
site 1/2motifs. In accordwith the apparent constitutivephosphor-
ylation of CK2 motifs in mammalian Mdc1 (Chapman and Jack-
son, 2008; Melander et al., 2008; Spycher et al., 2008; Wu et al.,
2008), we detected Ctp1 Ser-87/Thr-89 phosphorylation irre-
spective of whether the S. pombe cells had been treated with
aDNA-damagingagent (Figure4C). Significantly,we further noted
that theDNAdamage-dependent reduction inCtp1mobility previ-
ously attributed to phosphorylation byS. pombeorthologs of ATR
and ATM, Tel1, and Rad3 (Akamatsu et al., 2008) was not
observed in the Nbs1-deletion and FHA mutant strains and was
reduced or abolished in the 2TA and 3TA strains (Figure 4D).
Together, these data suggest a mechanistic link between Nbs1
FHA-binding activity and priming phosphorylation of Ctp1 by
CK2 as a prerequisite for additional DNA damage-dependent
Ctp1 phosphorylation by ATM/ATR family kinases.
Ctp1 Phosphosites Bind to Nbs1 and Promote
Resistance to DNA-Damaging Agents
The foregoing data prompted us to investigate whether Ctp1
phosphosites bind spNbs1 in vitro. This revealed tight spNbs1106 Cell 139, 100–111, October 2, 2009 ª2009 Elsevier Inc.binding to phosphorylated forms of both the Ctp1 site1 and
site 2motifs (Figure 5A; Table S1). Indeed, the site 2 peptide con-
taining both pSer-87 and pThr-89 bound some 30-fold tighter
than a diphosphorylated site 1 peptide (pSer-77/pThr-79), with
an apparent Kd of50 nM that is among the highest-affinity inter-
actions for any FHA domain reported to date. Significantly, inter-
actions of spNbs1 with site 1 or site 2 peptides phosphorylated
only on pThr-79 or pThr-89 were 8-fold and 10-fold weaker than
those for the respective diphosphorylated versions. This effect
recapitulates the 17-fold reduced affinity observed for hNbs1
binding to the mono- versus diphosphorylated Mdc1 peptide
(Figure 5B), demonstrating a remarkably similar pattern of spec-
ificity for the fission yeast and human Nbs1 orthologs.
To further investigate the potential functional significance of
Ctp1 sites 1 and 2 as binding epitopes for spNbs1, we generated
mutant strains bearing alanine substitutions of Thr-79, Thr-89, or
both. Perhaps surprisingly, both the individual and double-site
Ctp1 mutants largely corrected the slow-growth and DNA-
damage hypersensitivity phenotypes of Ctp1-defective cells
(Figure 5C). Nevertheless, while displaying little or no hypersen-
sitivity toward low doses of the radiomimetic drug phleomycin
(data not shown), the double mutant did display some hypersen-
sitivity to higher phleomycin levels. We thus speculated that
phosphorylation of a third threonine, Thr-78 within Ctp1 Site 1,
might also contribute to Ctp1 function and, accordingly, we
found that the spNbs1 FHA/BRCT2 region bound tightly to
a Ctp1 peptide containing singly phosphorylated Thr-78 with
an apparent Kd of 0.2 mM (Table S1). Moreover, while a mutant
strain bearing the single T78A mutation displayed wild-type
growth and drug-sensitivity profiles, combination of the T78A,
T79A, and T89A mutations yielded a strain that was hypersensi-
tive to camptothecin, phleomycin, and MMS, albeit not to the
same degree as the Ctp1 null strain (Figure 5A).
In order to investigate the specificity of spNbs1 interactions
with the site 1 and site 2 Ctp1 motifs, we constructed a strain
containing alanine mutations of Thr-78, -79, -89, and -71 that
is located immediately N-terminal to the site 1 region, but not
within a SDTD-like sequence. In this case, the additional muta-
tion did not further increase damage sensitivity (Figure S5A),
a lack of effect that correlated well with the absence of sig-
nificant binding of spNbs1 FHA/BRCT2 to a pThr-71 phospho-
peptide (Figure S5B; Table S1). These and additional data
(Figure S6; Table S1) revealed an ‘‘extended’’ specificity of the
spNbs1 FHA domain beyond that normally observed for such
modules. Binding absolutely depends on the presence of at
least one pThr, and a further preference for glutamate/aspartate
is evident at the pThr +3 position that is often a major determi-
nant of FHA specificity (Durocher et al., 2000). For Thr-79 and
Thr-89, additional serine phosphorylation in the 2 position
increases affinity by10-fold. However, other positions, notably
those in the C-terminal acidic stretch of the motif, contribute
significantly to binding affinity reflecting a plasticity of the
Nbs1 FHA domain that appears to have evolved to exploit and
accommodate additional sequence requirements for Ctp1
phosphorylation.
Taken together, the above findings strongly suggested that
S. pombeMRN, through the Nbs1 FHA domain, interacts directly
with Ctp1 through redundant CK2 phosphorylation motifs. To
Figure 5. Phospho-Dependent Nbs1 Interactions with Ctp1 Promote DNA-Damage Resistance
(A) ITC titrations of spNbs1 with the pSDpTD-like motifs from Ctp1-Site 1 (upper left) and Ctp1-Site 2 (lower left) are depicted by closed squares. Each panel also
shows the reduced affinities for singly phosphorylated pThr peptides of the same length and sequence (open circles).
(B) ITC titrations of hNbs1 with monophosphorylated (SDpTD, closed squares) and diphosphorylated (pSDpTD, open circles) Mdc1 motifs.
(C) Mutation of CK2-like sites in Ctp1 hypersensitizes cells to DNA double-strand break inducing agents. Five-fold serial dilutions of the indicated strains were
plated on control medium (YPA) or medium supplemented with the indicated drugs and then incubated for 3 days at 30C.
(D) DNA-damage sensitivity due to deletion of the FHA domain and BRCT1 is suppressed by N-terminal fusion with Ctp1. The ctp1:nbs1FHA/BRCT1D strain was
generated by replacement of the nbs1 gene with a transgene encoding the chimeric fusion protein illustrated in the schematic. SG4 denotes a Ser-Gly poly-linker
at the fusion site (Nbs1 Asp-221). Growth assays were performed as in Figure 5C.test this idea, we first created an S. pombe strain containing
Nbs1 in which the FHA-BRCT1 region had been deleted. As
expected, these cells exhibited a severe hypersensitivity to low
levels of DNA-damaging agents closely resembling the pheno-
types of the G103D FHA mutant and Nbs1D strains (Fig-
ure 5D). Strikingly, however, hypersensitivity was completely
rescued when the Nbs1 protein lacking the FHA/BRCT1 region
was expressed as a fusion to full-length Ctp1 (Figure 5D). The
ability of this fusion to circumvent a requirement for the FHA/
BRCT1 domain thus provided strong support for Ctp1 binding
as a primary function of the spNbs1 FHA/BRCT region.The Human Nbs1 BRCT-Repeat Domain Contains
a Second Phospho-Binding Site
Our spNbs1 structure revealed that the relative arrangement and
packing of the tandem BRCT motifs resembles that previously
observed in structures of other BRCT-repeat domains, many of
which display phosphopeptide-binding functions (Figure 6A).
SpNbs1 does not contain lysine and serine/threonine residues
known to make direct phosphate contacts in other BRCT-phos-
phoprotein complexes (Figure 6B). They are, however, present in
hNbs1 (Lys-160 and Ser-118), and although other positions
involved in accessory main-chain peptide interactions andCell 139, 100–111, October 2, 2009 ª2009 Elsevier Inc. 107
Figure 6. A Phospho-Binding Function for
the hNbs1 BRCT-Repeat Domain
(A) Structural conservation of the BRCT-repeat
domains from SpNbs1 (left) and the Brca1/Bach1
complex as an example of a BRCT-domain/phos-
phopeptide interaction (right) (PDB ID: 1T15).
BRCT1 and BRCT2 domains are colored green
and blue, respectively, while the BRCT-linker
region is shown in magenta. The Bach1 phospho-
peptide is drawn as a stick representation with
carbon atoms colored yellow.
(B) Residues involved in Brca1 BRCT-repeat
Bach1 phosphopeptide interactions shown in
a stick representation, are partially conserved in
hNbs1 but not in spNbs1.
(C) Mutation of potential phospho-binding resi-
dues in the hNbs1 FHA (R28A and S44A) and
BRCT domains (K160M) has a limited effect on
binding affinities for Mdc1 pSDpTD motifs but
reduces the stoichiometry by 2-fold in compar-
ison to the wild-type (see also Table S1). The
double mutant, S44A/K160M, effectively abol-
ishes binding.
(D) ITC measurements reveal that hNbs1 is able
to bind to a pSDpSD variant of Mdc1 (closed
squares) but not spNbs1 (open circles). Binding
is abolished by the K160M (BRCT repeat) mutation
(closed triangles) but unaffected by R28A in the
FHA domain (open squares).
(E) Interactions of hNbs1 and MDC1 requires the
phosphopeptide-binding activity of both the
hNbs1 FHA and BRCT domains. Immunopre-
cipitations were performed from 2 mg of nucle-
ase (Benzonase, Novagen) -treated whole-cell
extracts derived from HEK293 cells transiently
transfected with expression plasmids encoding
YFP (pEYFP2-N1), YFP2-NBS1 (NBS1 pEYFP2-
N1), or YFP2-NBS1 bearing either the R28A FHA
point mutation or the K160M BRCT1 point muta-
tion. Samples were immunoblotted with the indi-
cated antibodies. No interaction with Mdc1 is
seen, even in longer exposures.
*Wild-type hNbs1 binding to the Mdc1 pSDpTD
326–336 peptide is shown in Figure 2D; here, we
used a similar diphosphorylated peptide of the
same length but with a core consensus of all six
Mdc1 motifs (FIDpSDpTDVEEE).sequence-specific binding are not (Figure 6B), we nonetheless
speculated that the Nbs1 N terminus might possess dual phos-
pho-recognition surfaces. In this regard, and in contrast to
spNbs1, we noticed that titrations of wild-type hNbs1 with a
variety of Mdc1-derived pSDpTD peptides consistently showed
evidence of two interaction sites, manifested as binding stoichi-
ometries significantly and reproducibly greater than 1:1 (Fig-
ure 6C; Table S1). Moreover, althoughmutation of the conserved
phospho-binding residues in the hNbs1 FHA domain (Arg-28 or
Ser-42), or in BRCT1 (Lys-160) had surprisingly small apparent
effects on phosphopeptide-binding affinity (Figure 6C; Table
S1), each of these reduced the stoichiometry by 2-fold. These
findings suggested that the effects of mutations in each indi-
vidual domain were being partially obscured by interactions
mediated by the other. Indeed, while a single FHA mutation
(R27A) is sufficient to dramatically reduce phosphopeptide108 Cell 139, 100–111, October 2, 2009 ª2009 Elsevier Inc.binding in spNbs1, we found that binding to hNbs1 was only
abolished when both FHA and BRCT1 sites were disrupted in
a S42A/K160M double mutant.
To further explore the apparent dual phospho-bindingmode of
hNbs1, we attempted to ‘‘uncouple’’ FHA and BRCT-domain
contributions by using a peptide synthesized with a variant
pSDpSD motif that lacks a phosphothreonine and would not,
therefore, be expected to interact with the hNbs1 FHA domain.
In line with the lack of ITC evidence for an additional binding
site in spNbs1 and the absence of any of the characteristic
BRCT phospho-binding residues in this protein, no interaction
of spNbs1 with the pSDpSD peptide was detectable (Figure 6D).
In marked contrast, significant binding of the pSDpSD peptide to
both wild-type hNbs1 and the R28A hNbs1 FHA mutant was
maintained but, crucially, no interaction was seen with the
K160M BRCT1 mutant. Consistent with these and previous
biochemical analyses (Chapman and Jackson, 2008), tagged
wild-type hNbs1 expressed ectopically in human cells efficiently
coimmunoprecipitated Mdc1, while Mdc1 was undetectable in
immunoprecipitates of Nbs1 bearing either the R28A or the
K160M point mutation (Figure 6E). Thus, both FHA-dependent
and BRCT-dependent phospho-specific interactions by Nbs1
are required for its stable interactions with Mdc1 in cell extracts.
Collectively, these data establish a clear in vitro phospho-
dependent binding activity for the hNbs1 BRCT-repeat domain.
Furthermore, the lack of hNbs1 interactions with the monophos-
phorylated pSDTD or gH2AX peptides containing a single phos-
phoserine (Figures 4A and S3) implies a preference of the hNbs1
BRCT domain for doubly phosphorylated motifs that differs
considerably from previously reported pS/TxxF/Y phospho-
dependent BRCT specificities (Manke et al., 2003; Yu et al.,
2003). Consistent with this model, hNbs1 lacks the highly
conserved arginine corresponding to residue 1699 in Brca1
and residue 1933 in Mdc1 that mediates crucial contacts with
main-chain atoms of bound phosphopeptides. Taken together,
these observations point to a rather distinct overall phospho-
motif binding mode for the hNbs1 BRCT repeats, although
further structural analysis of hNbs1 phosphopeptide complexes
will clearly be necessary to ascertain the precise molecular basis
for such interactions.
DISCUSSION
Here we have presented a combined structural, biochemical,
and cell-biological investigation of the N-terminal region of the
key DSB repair and DNA damage-signaling protein, Nbs1. Our
crystallographic analysis has revealed a conserved supramodu-
lar FHA-BRCT2 architecture that, along with our supporting
biochemical data, explains the apparent functional inter-depen-
dence of the Nbs1 FHA and BRCT motifs first noted some time
ago (Cerosaletti and Concannon, 2003).
Our observation that the binding activities of fission yeast and
human Nbs1 fragments show a similar FHA-domain specificity
for pSDpTD-like CK2 motifs has allowed us to identify related
spNbs1 binding sites within S. pombeCtp1 that mediate interac-
tions necessary for resistance to DNA damage. Overall, our data
are in agreement with an independent structure-function anal-
ysis of fission yeast Nbs1 and its interactions with Ctp1 reported
in this issue of Cell (Williams et al., 2009). The resemblance of
these Nbs1 binding sites in Ctp1 to others located in budding
yeast Lif1 further suggests that interactions between Lif1 and
Xrs2 (Palmbos et al., 2008) employ a similar binding mode.
Significantly, both human and yeast Nbs1 showed increased
affinity for diphosphorylated sequences as compared with singly
phosphorylated motifs. This, together with the existence of
multiple SDTD motifs in Mdc1, Ctp1, and Lif1 and the combina-
torial effects of site 1 and site 2 mutations on Ctp1 function and
interactions with spNbs1, suggests that Nbs1 has evolved an
ability to respond to varying levels of overall phosphorylation of
its interacting partners.
Overall, the intimate association of the Nbs1 FHA and BRCT-
repeat domains observed in our structure suggests that the fixed
spatial relationship between the two regions may be important in
allowing a concerted mode of FHA- and BRCT-domain activity.Our cell-biological and biochemical approaches have shown
a phosphorylation-dependent binding capability for the human
Nbs1 BRCT-repeat domain that is exercised through interac-
tions distinct from those previously observed for the BRCT
repeats of Brca1 and Mdc1. The apparent necessity for binding
of the human Nbs1 BRCT-repeat domain to diphosphorylated
motifs is intriguing and contrasts the rather more accessory
effect of the additional phosphoserine on interactions of the
Nbs1 FHA domain. It is thus tempting to speculate that these
binding properties confer a degree of flexibility to hNbs1
responses through the use of separate phospho-binding
domains with distinct, but overlapping specificities. At the
molecular level, this arrangement could accommodate juxtapo-
sition of different protein partners, each primed through phos-
phorylation by upstream kinases, in a manner reminiscent of
14-3-3 function (Gardino et al., 2006). Alternatively, the FHA-
and BRCT-repeat domains might recognize dual phospho-
dependent interaction sites within a single molecule such as
Mdc1. In support of this, we have shown that individual mutation
of phospho-binding residues in either the FHA- or BRCT-repeat
domains of hNbs1 is sufficient to severely compromise its inter-
actions with Mdc1 in human cells, consistent with previously
reports that intact FHA- andBRCT-repeat domains of Nbs1 (Cer-
osaletti and Concannon, 2003; Wu et al., 2008) and more than
a singleMdc1 pSDpTDmotif (Spycher et al., 2008) are necessary
for MRN localization to DNA-damage foci in human cells.
In contrast to its human counterpart, the role of the spNbs1
BRCT-repeat domain remains unclear, and, consistent with the
absence of residues analogous to those imparting direct phos-
phate interactions in Mdc1, Brca1, and also hNbs1, we have
been unable to demonstrate a phospho-binding function for the
spNbs1BRCT-repeat domain.However, thepresence of alterna-
tive interaction surfaces in this domain that may mediate phos-
pho-dependent or phospho-independent interactions cannot
be discounted. Indeed, the phospho-independent binding capa-
bility reported for FHA domains (Li et al., 2002; Nott et al., 2009),
and originally described for BRCT-repeat domains in Brca1/
53BP1complexes (Derbyshire et al., 2002; Jooet al., 2002), could
specify additional binding functions for the Nbs1 N terminus,
expanding the versatility of this region as aplatform for promoting
DNA repair and DNA-damage checkpoint signaling.
EXPERIMENTAL PROCEDURES
Expression and Purification
Synthetic genes encoding spNbs1 (1–324) and hNbs1 (1–382) were produced
by GENEART AG (http://www.geneart.com/) and expressed in pET22b as
C-terminal (His)6 tag fusion proteins for purification utilizing a Ni-Sepharose
affinity chromatography followed by Source 15Q ion exchange and Superdex
75 size exclusion chromatography (GE Healthcare). Mutations were intro-
duced with the QuikChange protocol (Strategene), and all constructs were
verified by DNA sequencing. For preparation of selenomethionine (SeMet)-
labeled spNbs1, plasmid was transformed into B834 (DE3) cells (Novagen).
Protein expression was performed in supplemented M9 minimal media
(Molecular Dimensions) and purified as for the native protein. SeMet incorpo-
ration was estimated to be >98% by mass spectrometry.
Crystallization and Data Collection
Growth of diffraction quality crystals of SeMet incorporated spNbs1 was
aided by carboxypeptidase A digestion. Crystallization was carried out byCell 139, 100–111, October 2, 2009 ª2009 Elsevier Inc. 109
sitting-drop vapor diffusion with an Oryx8 nano-dispensing robot (Douglas
Instruments). Crystals grew at a protein concentration of 8 mg/ml against
a reservoir containing 0.1 M MES (pH 6.0), 0.1 M MgCl2, and 8% w/v PEG
6000. SAD data were collected at 100 K at the peak of the anomalous (f’’) sele-
nium signal on beamline I04 at the Diamond Light Source, UK from crystals
cryoprotected with 30% glycerol. Methods for crystal improvement along
with details of the structure solution/refinement and other biochemical proce-
dures are provided in the Supplemental Data.
Isothermal Titration Calorimetry
The affinities and thermodynamic parameters for hNbs1 and spNbs1 interac-
tions with synthetic phospho-peptides were determined by isothermal titration
calorimetry with a VP-ITC instrument (MicroCal) at 12C (spNbs1) or 18C
(hNbs1). hNbs1 samples were dialyzed extensively into 50 mM HEPES
(pH 7.5), 150 mM NaCl, 2 mM b-mercaptoethanol, and spNbs1 samples into
50 mM HEPES (pH 7.5), 50 mM NaCl, 2 mM b-mercaptoethanol. Prior to
use, all peptides were desalted and buffer exchanged using NAP-5 purification
columns (GE Healthcare) into the relevant buffer. In general, peptides (0.5–
1.5 mM) were titrated into 0.05 mM hNbs1 or spNbs1. Peptides were synthe-
sized by W. Mawby (University of Bristol), and their composition was verified
bymass spectrometry. Data were analyzed with Origin 7.0 software (Table S1).
Yeast Strains and Methods
S. pombe ‘‘503’’ (h+ ura4-D18, leu1-32, ade6-704) and ‘‘501’’ (h- smt0 ura4-
D18, leu1-32, ade6-704) were used to construct all strains used in this study.
nbs1 and ctp1 wild-type and mutant strains were generated either by recom-
binase-mediated cassette exchange from nbs1D or ctp1D base-strains
created as described (Watson et al., 2008) or in genetic crosses. Sp102 plas-
mids, a gift from H. Iwasaki, were maintained after transformation by selection
with LEU2. Yeast transformations were performed as described previously
(Suga and Hatakeyama, 2005). Strains used in this study are listed in Table S2.
Human Cell Culture, Transfection, and Immunoprecipitation
HEK293 cells were transfected with expression plasmids with Fugene 6
(Roche) according to the manufacturer’s instructions. Cells were lysed in Ben-
zonase lysis buffer (40 mM NaCl, 25 mM Tris [pH 7.5], 2 mMMgCl2, 0.5% NP-
40, EDTA-free protease inhibitor cocktail [Roche], 25U/ml Benzonase [Nova-
gen]), incubated 4C for 10 min before the NaCl concentration was adjusted
to 450 mM, and then incubated for a further 30 min. Lysates were clarified
by centrifugation, and 2 mg of lysates were adjusted to the final buffer condi-
tions: 225mMNaCl, 25mMTris (pH 7.5), 10%w/v glycerol, 2 mMEDTA, 1mM
DTT, 0.5% NP-40, protease inhibitors (Complete, Roche), and phosphatase
inhibitor cocktail (Sigma). Immune complexes were captured with Protein-G
Dynabeads (Dynal) coupled to 0.5 mg anti-GFP antibody for 1 hr at 4C, and
beads extensively washed with the above buffer.
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Atomic coordinates and structure factors have been deposited with the
Protein Data Bank under accession numbers 3I0M and 3I0N.
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